Recruiting

Testing a new Alzheimer's treatment for safety and how the body processes it

Plain-English translation of NCT07758595 on ClinicalTrials.gov ↗ · Source last updated August 2026 · Translation generated August 2026 · How we translate trials

Read our Alzheimer's Disease research guide →

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new medication called to see if it is safe and how your body processes it. The study includes both healthy people and people with mild to moderate Alzheimer's disease. Researchers want to understand whether this treatment could eventually help slow or treat Alzheimer's.

Alzheimer's disease is a serious condition that affects memory and thinking, and there is a need for new treatments. This study is an early step to see if this medication might be a safe option for people with Alzheimer's in the future.

Do you qualify?

You likely qualify if…

you are between 18 and 60 years old (if you are healthy) or between 50 and 75 years old (if you have Alzheimer's disease)
you have been diagnosed with mild to moderate Alzheimer's disease or mild cognitive impairment due to Alzheimer's (for the Alzheimer's group)
you have a BMI between 18 and 32 and weigh at least 45–50 kg (about 100–110 pounds)
you are not able to have children, or if you are male, you agree to use two forms of contraception during the study
you show signs of Alzheimer's disease on blood tests or brain imaging (amyloid PET scan) if you are in the Alzheimer's group

You likely don't qualify if…

you have been hospitalized in the 4 weeks before screening
you are pregnant, breastfeeding, or have a positive pregnancy test
you have had a cancer diagnosis within the past 5 years (unless it was fully treated and low-risk)
you have received previous anti-amyloid or anti-tau immunotherapy or participated in gene therapy or cell therapy
you have other serious medical conditions affecting your heart, liver, kidney, or brain that could interfere with the study

What participation looks like

You will receive either the new medication or a placebo (inactive substance) as a single dose or multiple doses, depending on which group you are in. You will have regular visits to the clinic where researchers will check your health, take blood samples, and monitor how your body responds to the treatment. The study involves safety testing and checking how the medication moves through your body over time.

AI-generated summary from trial data · Aug 26, 2026 · Not medical advice

Trial locations(1 site)

United Kingdom

Clinical Site(s), Manchester